What will be the public perception of Andrew Ferguson's performance as FTC Chair by end of 2024?
Very Favorable • 25%
Somewhat Favorable • 25%
Somewhat Unfavorable • 25%
Very Unfavorable • 25%
Polls or surveys conducted by reputable polling organizations
Trump Appoints Andrew Ferguson as FTC Chair, Nominates Mark Meador as Commissioner
Dec 10, 2024, 11:56 PM
President-elect Donald Trump announced the appointment of Andrew N. Ferguson as the next Chair of the Federal Trade Commission (FTC), succeeding Lina Khan whose term expired in September. Ferguson, a Republican commissioner sworn in on April 2, 2024, previously served as chief counsel to Senate Republican Leader Mitch McConnell and clerked for Supreme Court Justice Clarence Thomas. He is recognized for his stance against Big Tech censorship and his commitment to protecting freedom of speech, aiming to tackle perceived censorship of conservative viewpoints online. Ferguson also led Senator Chuck Grassley's team during the Justice Brett Kavanaugh confirmation process. Trump's selection has been praised by Senator Grassley, who called Ferguson an "excellent choice to take on big tech and big pharma." Trump described Ferguson as "the most America First, and pro-innovation FTC Chair in our country's history." In addition, Trump nominated Mark R. Meador, a partner at Kressin Meador Powers LLC and former Deputy Chief Counsel for Antitrust and Competition Policy to Senator Mike Lee, to be a Commissioner on the FTC. Meador is regarded as a leading conservative legal scholar in antitrust law.
View original story
Mixed • 25%
Neutral • 25%
Negative • 25%
Positive • 25%
Nomination Withdrawn • 34%
Confirmed • 33%
Rejected • 33%
More lenient regulation • 25%
Other • 25%
No significant change • 25%
Stricter regulation • 25%
Other • 25%
Antitrust enforcement • 25%
Consumer protection • 25%
Big Tech regulation • 25%
Another Appointee • 25%
Mark Meador • 25%
Andrew Ferguson • 25%
Vacant • 25%
No significant policy change • 25%
Increased focus on online censorship • 25%
Focus on consumer privacy • 25%
Focus on antitrust issues • 25%
No change • 25%
Other • 25%
Less aggressive • 25%
More aggressive • 25%
Very positive • 25%
Somewhat positive • 25%
Negative • 25%
Neutral • 25%
No Misconduct Found • 25%
Minor Misconduct Found • 25%
Severe Misconduct Found • 25%
Significant Misconduct Found • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Consumer Protection • 25%
Pharmaceutical Regulation • 25%
Big Tech Regulation • 25%
Antitrust Enforcement • 25%